Home News Aqilion on phase I results and potential IPO

Aqilion on phase I results and potential IPO

Sarah Fredriksson, vd, Aqilion

Aqilion on phase I results and potential IPO

10 November, 2023

Aqilion recently announced positive results from the phase I study with their candidate AQ280. The candidate targets eosinophilic esophagitis and is tested in Aqilion’s Regulus programme. CEO Sarah Fredriksson visited BioStock’s studio to tell us more about the phase I results and the plans for a potential IPO.

See the interview with Aqilion’s CEO Sarah Fredriksson below.

YouTube video

The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.

Prenumerera på BioStocks nyhetsbrev